Ide574, Fulvestrant Injection
Non-Small Cell Lung Cancer (Nsclc), Castration-Resistant Prostate Cancer (Crpc), Er+, Her 2- Breast Cancer, Microsatellite Stable (Mss) Colorectal Carcinoma
Phase I/II
Recruiting
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
Apr 01, 2026
Ide034
Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Head And Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Colorectal Cancer, Endometrium Cancer, High Grade Serous Ovarian Cancer, Castration-Resistant Prostate Cancer
Phase I
Recruiting
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Mar 19, 2026
―
Ide397, Ide892
Non-Small Cell Lung Cancer Nsclc, Pleural Mesothelioma, Bladder Cancer, Gastric Adenocarcinoma, Mesothelioma, Gastroesophageal Cancer (Gc), Nsclc Adenocarcinoma, Adenocarcinoma Of Esophagus, Squamous Cell Car. - Esophagus, Urothelial Carcinoma (Uc), Peritoneal Mesothelioma
Phase I
Recruiting
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Nov 13, 2025
Darovasertib, Primary Local Therapy
Uveal Melanoma
Phase III
Recruiting
Neoadjuvant Darovasertib in Primary Uveal Melanoma
Jun 03, 2025
―
Gsk4418959, Pd-1 Inhibitor
Rectal Cancer, Colon Cancer, Neoplasms, Colorectal, Solid Tumor, Endometrial Cancer
Phase I/II
Recruiting
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Nov 26, 2024
―
Darovasertib
Uveal Melanoma
Phase II
Recruiting
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
Jun 06, 2023
―
Pembrolizumab, Ide-161
Head And Neck Cancers, Advanced Or Metastatic Solid Tumors, Endometrial Cancer, Nsclc, Ovarian Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer
Phase I
Recruiting
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Mar 17, 2023
―
Sacituzumab Govitecan, Paclitaxel, Docetaxel, Ide397
Solid Tumor
Phase I
Recruiting
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
Mar 09, 2021
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does IDEAYA Biosciences (30J) have in its pipeline
30J is currently developing the following drugs: Ide574, Fulvestrant Injection, Ide034, Ide397, Ide892. These drug candidates are in various stages of clinical development as the company works toward FDA approval.